{"id":"NCT00091819","sponsor":"Cumberland Pharmaceuticals","briefTitle":"Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus","officialTitle":"A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2006-06","completion":"2006-06","firstPosted":"2004-09-21","resultsPosted":"2009-12-08","lastUpdate":"2019-01-16"},"enrollment":862,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Staphylococcal Skin Infection"],"interventions":[{"type":"DRUG","name":"Telavancin","otherNames":["VIBATIV","TD-6424"]},{"type":"DRUG","name":"Vancomycin","otherNames":[]}],"arms":[{"label":"Telavancin","type":"EXPERIMENTAL"},{"label":"Vancomycin","type":"ACTIVE_COMPARATOR"}],"summary":"Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.","primaryOutcome":{"measure":"Clinical Response","timeFrame":"7-14 days following end of antibiotic treatment","effectByArm":[{"arm":"Telavancin","deltaMin":323,"sd":null},{"arm":"Vancomycin","deltaMin":321,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["18444791","19095213","22416054"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":426},"commonTop":["Nausea","Dysgeusia","Headache","Vomiting","Insomnia"]}}